Back

Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3

17 May 2025 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award (YIA) Basic Science Cardio-Oncology HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Vincenzo Quagliariello

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

3 More presentations in this session

Presentation thumbnail
Engineering genetic resilience for cardiometabolic HFpEF: the crucial role of redox homeostasis
Doctor M. Pepin (Stanford, US)
Abstract Slides Video
Presentation thumbnail
Phospholamban antisense therapy reduces phospholamban aggregation and enhances calcium and contractile kinetics in human phospholamban cardiomyopathy
Mr F. Deiman (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
A multifactorial porcine model of cardio-metabolic HFpEF highlights miR-483-3p as a promising target therapy
Miss K. Kohlat (German Heart Center Of Charite Berlin, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award (YIA) Basic Science
Video

The Event

Event poster

Heart Failure 2025

17 May 2025 13:45 CET
You may be interested in
thumbnail
Congress Presentation
GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after three years of observation.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources